drugset / Trial / NCT00814606

A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C

NCT00814606

Phase 2 Withdrawn University of Chicago
NaSingle-groupOpen-labelTreatment

Summary

This study seeks to evaluate the safety and efficacy of taking fluvastatin along with peginterferon alfa in previous partial responders with genotype 1 HCV.

Timeline

Start
2010-02
Primary completion
2010-10
Completion
2010-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluvastatin Other / unclassified 80 mg
Background Peginterferon alfa-2a Protein / enzyme biologic 180 ug/ml Subcutaneous
Background Ribavirin Small molecule 1000 mg Oral
Background Ribavirin Small molecule 1200 mg Oral